Penumbra (PEN) Reports THUNDERBOLT Study Success As First Stroke Treatment Use Begins

Simply Wall St.

Jul 23

Penumbra (NYSE:PEN) reported key clinical results from its THUNDER study, indicating the THUNDERBOLT stroke treatment system met safety and effectiveness goals. The THUNDERBOLT system has now seen its...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2653402767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653402767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653402767?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-07-23 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653402767","market":"hk","top_or_hot":-1,"title":"Penumbra (PEN) Reports THUNDERBOLT Study Success As First Stroke Treatment Use Begins","media":"Simply Wall St.","content":"<div>\n<p>Penumbra (NYSE:PEN) reported key clinical results from its THUNDER study, indicating the THUNDERBOLT stroke treatment system met safety and effectiveness goals. The THUNDERBOLT system has now seen its...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-pen-reports-thunderbolt-study-success-as-first-stro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penumbra (PEN) Reports THUNDERBOLT Study Success As First Stroke Treatment Use Begins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenumbra (PEN) Reports THUNDERBOLT Study Success As First Stroke Treatment Use Begins\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-23 19:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-pen-reports-thunderbolt-study-success-as-first-stro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Penumbra (NYSE:PEN) reported key clinical results from its THUNDER study, indicating the THUNDERBOLT stroke treatment system met safety and effectiveness goals. The THUNDERBOLT system has now seen its...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-pen-reports-thunderbolt-study-success-as-first-stro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEN.AU","symbol_name":"PENINSULA ENERGY LTD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-pen-reports-thunderbolt-study-success-as-first-stro","article_id":"2653402767","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/penumbra-pen-reports-thunderbolt-study-success-as-first-stro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653402767","pubTimestamp":1784805789,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Penumbra (NYSE:PEN) reported key clinical results from its THUNDER study, indicating the THUNDERBOLT stroke treatment system met safety and effectiveness goals.\nThe THUNDERBOLT system has now seen its first clinical use following recent FDA clearance, with initial adoption at a leading neuroscience institute.\nThese updates add new clinical and real-world data points beyond prior announcements on the FORWARD study and regulatory clearance.\n\nFor investors tracking Penumbra, the THUNDERBOLT...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEN.AU":"PENINSULA ENERGY LTD","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","PEN":"Penumbra Inc","BK7083":"煤与消费用燃料"},"translate_title":"Penumbra (PEN) 报告 THUNDERBOLT 研究取得成功，首次中风治疗开始使用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN.AU":1.5,"PEN":1.5},"content_text":"Penumbra (NYSE:PEN) reported key clinical results from its THUNDER study, indicating the THUNDERBOLT stroke treatment system met safety and effectiveness goals. The THUNDERBOLT system has now seen its first clinical use following recent FDA clearance, with initial adoption at a leading neuroscience institute. These updates add new clinical and real-world data points beyond prior announcements on the FORWARD study and regulatory clearance.  For investors tracking Penumbra, the THUNDERBOLT system sits at the core of the company’s neurovascular portfolio, focused on devices for stroke intervention. The latest clinical outcomes arrive as stroke treatment technologies continue to be an area of medical device development, with companies seeking solutions that can be used efficiently in real-world hospital settings. The combination of THUNDER study results and first clinical adoption provides investors with additional information on how this new platform is beginning to be used beyond trials. As more centers gain experience with THUNDERBOLT, the pace and breadth of adoption may become a reference point for assessing Penumbra’s position in the stroke treatment market. Stay updated on the most important news stories for Penumbra by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Penumbra. NYSE:PEN Earnings & Revenue Growth as at Jul 2026 2 things going right for Penumbra that this headline doesn't cover. AdvertisementInvestor Checklist: What This THUNDERBOLT Update Means for Penumbra Quick Assessment  ✅ Price vs Analyst Target: Penumbra trades at US$316.50, around 13% below the US$362.54 analyst price target. ❌ Simply Wall St Valuation: Shares are described as trading about 47% above estimated fair value. ✅ Recent Momentum: The stock is roughly flat over 30 days, with a 0.1% return.  There's only one way to know the right time to buy, sell or hold Penumbra. Head to Simply Wall St's company report for the latest analysis of Penumbra's Fair Value. Key Considerations  📊 Positive THUNDERBOLT safety and effectiveness data, plus first clinical use, provide additional support for Penumbra’s stroke treatment portfolio. 📊 Monitor how quickly additional hospitals adopt THUNDERBOLT and how this affects revenue and earnings relative to the current P/E of about 72.8x. ⚠️ With the stock flagged as 47% above estimated fair value, any slower than expected uptake of THUNDERBOLT could affect sentiment.  Dig Deeper For the full picture including more risks and rewards, check out the complete Penumbra analysis. Alternatively, you can check out the community page for Penumbra to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}